Lataa...
Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment
Durvalumab, a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules, is increasingly used in advanced neoplasias. Durvalumab use is associated with increased immune-related adverse events. We re...
Tallennettuna:
| Julkaisussa: | Endocrinol Diabetes Metab Case Rep |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Bioscientifica Ltd
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8115434/ https://ncbi.nlm.nih.gov/pubmed/31310083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-19-0045 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|